ICER releases draft evidence report on treatments for amyotrophic lateral sclerosis

14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public ...

Read more →

ICER publishes evidence report on gene therapy for beta thalassaemia

2 June 2022 - Evidence judged to demonstrate that beti-cel provides net health benefit to patients with transfusion-dependent thalassaemia. ...

Read more →

ICER to assess treatment for vasomotor symptoms associated with menopause

1 June 2022 - Report will be subject of Midwest CEPAC meeting in December 2022; draft scoping document open to ...

Read more →

ICER publishes protocol for annual assessment of drug coverage policies that present barriers to fair access

23 May 2022 - The ICER will evaluate whether the 15 largest US commercial payers, the 2 largest state health ...

Read more →

ICER publishes final evidence report and policy recommendations on outpatient treatments for COVID-19

10 May 2022 - Independent appraisal committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit ...

Read more →

ICER to assess gene therapies for haemophilia A and B

5 May 2022 - Report will be subject of CTAF meeting in November 2022; draft scoping document open to public ...

Read more →

ICER’s favourable assessment of Bluebird Bio’s gene therapy Zynteglo may have important pricing and reimbursement implications

5 May 2022 - ICER evaluated the clinical and cost-effectiveness - as well as budgetary impact - of one of two ...

Read more →

ICER to assess treatments for multiple sclerosis

21 April 2022 - Report will be subject of New England CEPAC meeting in January 2023; draft scoping document open ...

Read more →

ICER publishes 2022 research protocol for assessing unsupported price increases on prescription drugs

14 April 2022 - Final assessment to be published on 6 December 2022. ...

Read more →

ICER releases draft evidence report on gene therapy for beta thalassaemia

13 April 2022 - Public comment period now open until 10 May 2022; requests to make oral comment during public ...

Read more →

ICER publishes white paper evaluating reforms to orphan drug development, pricing and coverage

7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...

Read more →

ICER publishes evidence report on treatments for COVID-19

28 March 2022 - Current evidence suggests all four drugs under review have prices reasonably aligned with patient benefits. ...

Read more →

ICER publishes evidence report on novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects

17 March 2022 - Due to the FDA action on plinabulin, ICER will not hold a public meeting but has produced ...

Read more →

ICER publishes research protocol for assessing price increases of prescription drugs in California

16 March 2022 - Final assessment to be published on 13 October; drugs to be evaluated are those identified through California’s ...

Read more →

ISPOR launches “About Real-World Evidence” content

8 March 2022 - Introductory information is designed to make RWE more accessible for health care audiences. ...

Read more →